Figure 2.

Tumor response by irRECIST across time. This spider plot demonstrates the tumor measurements from baseline using irRECIST criteria during the course of treatment with pembrolizumab in the three patients. Patient 1 and 2 had progression of disease prior to stopping treatment while patient 3 stopped treatment due to treatment-related toxicity. Patient 1 and 3 had unconfirmed partial responses as defined by irRECIST criteria. Despite a significant reduction in the size of the target lesions on her initial scan at cycle 3 with partial response, her follow-up scans at cycle 6 and cycle 9 demonstrated the appearance of new lesions and progression of non-measurable lesions; the best objective response is stable disease. Patient 3 had an unconfirmed partial response due to treatment discontinuation (after cycle 5) following initial evaluation of partial response; the best objective response is stable disease.